Medical Knowledge Sharing

Apparatus

Stavudol Paediatric Indication Approved For The Treatment Of Children Aged 3 Months And Older With Complicated Intra-Abdominal Infections

There is an urgent clinical need for new antimicrobial drugs to break through the dilemma of cIAI treatment in children and address the growing challenge of drug resistance.

Medical

Pfizer's New Treatment Elranatamab Receives FDA Breakthrough Therapy Designation For Relapsed Or Refractory Multiple Myeloma

Pfizer's new treatment, Elranatamab, has received Breakthrough Therapy designation from the FDA for the treatment of patients with relapsed or refractory multiple myeloma. Data from the trial showed a patient efficacy rate of 61.0% and that once the therapy is effective, efficacy is maintained for more than six months in over 90% of patients!